Medro Tirzepatide Review: Cost, a Verified LegitScript Seal & Honest Verdict (2026)

Medro has a genuine LegitScript seal (#50716646) served directly from LegitScript's own CDN, matching the ranking's claim exactly. Every fact here comes from the company's own published program.

What Medro is

Medro (Medro Health Technologies, Inc.) is a telehealth brand, offering compounded semaglutide and tirzepatide plus brand-name GLP-1s when clinically eligible, via a partner medical group. LegitScript certified, available in all 50 states.

What Medro costs

Tirzepatide starts at $299/month, with tiered pricing shown before checkout and no membership fee. Prices drop with longer commitments — semaglutide to $149/month and tirzepatide to $224/month on a 12-month plan. Final cost is described as illustrative and confirmed only at checkout.

The brand-vs-compounded question

Medro offers compounded GLP-1s, with brand-name options when clinically appropriate. Compounded tirzepatide is pharmacy-made, not itself an FDA-approved finished drug, and was not the specific product studied in the pivotal trials; the brand option is the exact molecule and dose that was. See our guide to whether compounded tirzepatide is still legal in 2026 for the regulatory picture.

How the care model holds up

Medro's real strengths: a genuinely verified LegitScript seal, plus no membership fee, free expedited shipping, all-50-state coverage, and prices that drop with longer commitments. The trade-offs: it doesn't name its compounding pharmacy or clinical partner medical group, so the fulfillment chain isn't independently verifiable, pricing is described as illustrative with the final number shown only at checkout, and it's a very new brand (2026, trademark pending) with a short track record. As with any GLP-1 program, confirm your actual checkout price before committing; tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning — see our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Judge the provider on price, oversight and disclosure; judge the molecule on its trials. Tirzepatide's are strong — roughly 15–21% of body weight over 72 weeks in SURMOUNT-1¹, and better than semaglutide head-to-head² — but they were run on the brand drug at FDA-approved doses. Our tirzepatide evidence guide has the full picture.

The honest verdict

Medro's genuinely verified LegitScript seal and no-membership pricing structure are real positives, confirmed directly, but the unnamed compounding pharmacy and clinical partner leave a real verification gap, and it's a genuinely new brand without much track record yet. For a similarly LegitScript-verified provider with a longer track record, compare it against Mevo Health or CoreAge Rx. See our best tirzepatide providers ranking for the full field.